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2 
Abstract 
 
Background: Despite the recommendations contained in the guidelines, a general rise in 
non-surgical treatments and declining use of total laryngectomy has occurred during the 
last decades, as well as some evidence of declining survival for advanced laryngeal 
cancer in many countries. 
Goal: To compare the results of surgical and non-surgical approach for T4a laryngeal 
cancer in term of curative effects, complications, and functional results by means of a 
systematic review of the more recent literature. 
Recent findings: Most recent data clearly demonstrate the superiority of total 
laryngectomy and post-operative radiotherapy, which produce a substantial long-term 
control and survival rates for patients with T4 larynx cancer. The most negative prognostic 
factor is represented by N status. Open partial laryngectomy, to the light of good and 
encouraging oncological/functional results, could represents an alternative to total 
laryngectomy for selected patients affected by laryngeal cancer in specific T4a 
subcategories, i.e. limited anterior extension. Considering the worse oncologic results, 
principally in patients with poor general conditions and T4a cancer, non-surgical larynx 
preservation should only be addressed to carefully selected patients who refused total 
laryngectomy, characterized by more limited T4a disease, minimal involvement through 
the cartilage and without pre-treatment derangement of laryngeal functions. 
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Introduction  
 
Laryngeal cancer (LC) is among the most common cancers of the head and neck, with 
about 110.000 to 130.000 new cases diagnosed worldwide annually, representing the 2% 
of the malignant neoplasms and the 60% of cervico-cephalic tumors [1].  
Survival rates of LC patients range from 73-92% for the early stage disease (I - II) to 50-
64% for the advanced stage disease (III - IV) [2]. The latter is associated with a high rate 
of loco-regional relapse and cancer-related death. The overall survival (OS) of advanced 
stage LC is negatively affected by T status and the N status, which have been recognized 
as independent prognostic factors in the literature [3]. 
The LC treatment relies on many available therapeutic approaches: the overarching goal 
of all of them is to maximize survival and, whenever possible, preserve voice and 
swallowing function. The National Comprehensive Cancer Network (NCCN) Clinical 
Practice Guidelines in Oncology [4] indicate the follows: 
1. patients suffering from T1, T2 and selected T3 LC should be initially treated with the 
aim to preserve the larynx, using transoral laser microsurgery (TLM), partial 
laryngectomy (OPHL) or radiotherapy (RT)  
2. patients suffering from T3 LC amenable to total laryngectomy (TL) can of course be 
treated with up-front surgery but better should be addressed to organ sparing 
protocol by concurrent chemoradiotherapy (CCRT) or induction chemotherapy 
followed by radiotherapy (IC-RT) in order to preserve the larynx and its functions. 
3. TNM classification system of LC (VII edition) [5] divided T4 into 2 categories: T4a, 
moderately advanced local disease, defined as tumors invading through the thyroid 
cartilage and/or invading tissues beyond the larynx (e.g. trachea, soft tissues of neck 
including deep extrinsic muscle of the tongue, strap muscles, thyroid or esophagus) 
and T4b, very advanced local disease, not eligible for surgery.  
Patients suffering from T4a LC should be treated with up-front TL in the majority of 
cases, leaving the organ sparing options to selected patients who decline surgery.    
For a century until the 1980s, up-front TL was considered the only therapy for patients with 
locally advanced LC [6]. 
Although this strategy can provide a good disease loco-regional control (LRC), it is 
associated with a negative impact on patients’ quality of life (permanent tracheostomy and 
loss of natural voice) [7]. For this reason, organ-sparing protocols, including non-surgical 
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options, as chemo-radiotherapy, and surgical options, as TLM or OPHL, have begun to be 
considered as reliable alternatives to TL. 
Starting from 1991, several clinical studies (Table 1) had analyzed organ-sparing 
potentialities in the non-surgical management of advanced LC, with confident results; 
consequently, the therapeutic trend for the treatment of advanced laryngeal cancer had 
progressively shifted from primary TL toward non-surgical organ preservation approaches. 
The era of chemo-radiation therapy in laryngeal oncology had taken off.  
In 1991, the first pivotal study was conducted by the Laryngeal Cancer Study Group of the 
Department of Veterans Affair (VA). They investigated in good responder patients with 
locally-advanced LC whether IC-RT could represent a better approach respect to TL 
followed by post-operative radiotherapy (TL-PORT) in terms of OS and organ sparing. This 
study showed a new role for chemotherapy in patients with advanced disease, 
demonstrating that a treatment strategy involving IC-RT could be effective in preserving 
the larynx in a high percentage of patients, without compromising overall survival [8]. 
The Radiation Therapy Oncology Group (RTOG 91-11) confirmed the feasibility and the 
effectiveness of a chemo-radiation approach. In a large trial published in 2003, in fact, 
RTOG compared the outcomes obtained with cisplatin plus fluorouracil IC-RT, CCRT and 
RT alone, detecting a higher laryngeal preservation and locoregional control after the 
treatment with CCRT [9].  
The efforts to improve patient quality of life without affecting the OS clearly altered the 
perception about treatment modalities. Clinical trials, and consequently guidelines that 
derived from, demonstrated that TL-PORT had better results in terms of OS on T4a tumors 
with evident progression through cartilage [10, 11, 4]. Notwithstanding, many countries 
and institutions perceived the organ preservation protocols as a TL replacement in the 
treatment of locally advanced LC. Thus, during the last 20 years, TL was increasingly 
considered just as a salvage surgery after the failure of organ preservation treatments [12]. 
Countries extensively adopting organ sparing protocols have seen a sharp increase in LC 
mortality rates, but they have persisted stable or reduced, where TL continued to be the 
standard treatment for advanced LC [13]. 
Starting from these considerations, controversies concerning the correct treatments of T4a 
LC, and the role of TL as up-front treatment are arguments nowadays deeply felt. 
The most recent literature explored these critical issues, bringing arguments in favor of the 
return to more traditional surgical approaches in the treatment of locally advanced 
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laryngeal cancer. Meanwhile, it was highlighted the therapeutic possibility to undergo 
partial laryngeal surgery for T4 tumors after a rigorous selection of patients. 
 
Recent survey comparing surgical and non-surgical approaches for patients with 
T4a Larynx cancer 
 
The larynx loss due to surgical treatment brings several functional morbidities. Thus, it was 
one of the first cancer sites in the head and neck district to be considered for preservation 
by the employment on non-surgical therapeutic approaches. This scenario was also 
spurred by a greater potential of salvage surgery if compared with other cancer sites [14]. 
In the last five years, several studies (Table 2) compared survival and functional outcomes 
of patients affected by advanced stage LC (T3 -T4a) and treated distinctly by total 
laryngectomy and post-operative radiotherapy (TL-PORT), open partial laryngectomy 
(OPHL), concurrent radio-chemotherapy (CCRT) or RT alone. The main analyzed end-
point token into accounts were overall survival (OS), disease-free survival (DFS), disease 
specific survival (DSS), locoregional control (LRC), and different functional outcomes (e.g. 
laryngectomy free survival - LxFS, laryngoesophageal dysfunction free survival - LED, 
actuarial freedom from laryngectomy -  FFL, actuarial freedom from laryngoesophageal 
dysfunction-free survival - FFLED). 
The majority of them detected significant improvements in terms of oncological outcomes 
(OS, DFS, DSS, and LCR) only for patients affected by T4a LC undergoing TL-PORT, if 
compared to those treated by CCRT or RT alone. This is in agreement with the Larynx 
preservation Consensus Panel recommendations for clinical trial [10] that consider 
patients with T4a disease as ineligible for laryngeal preservation protocols, and with the 
recent National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in 
Oncology [4], American Society of Clinical Oncology (ASCO) guidelines [12] and Italian 
association of Medical Oncology (AIOM) guidelines [11], which recommend up-front TL-
PORT in T4a glottic and supraglottic LC and listed CCRT and IC as options only if TL is 
declined. 
Nevertheless, some Authors concluded that disappointing results regarding OS of patients 
with locally advanced stage LC after non-surgical treatment could be due to an etiological 
shift, leading to a progressive reallocation of cases between the different sites of the larynx 
[15]. However, these studies were based on long-term analyses of patient cohorts from 
countries in which employment rate of TL was substantially unchanged and chemo-
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radiotherapy was used in a minority of cases. This situation made them unable to verify 
the improved survival associated with the TL. 
Nowadays, the most recent literature recommends caution in indicating non-operative 
chemo-radiotherapy to treat patients with T4a LC. Furthermore, when pursued, this 
challenging option requires both a multidisciplinary case evaluation and a frank discussion 
about options and expectations with the patient. Critical is, indeed, not only the tumor 
extent or the laryngeal function prior the treatment, but also the expected tolerance to 
treatment on the basis of recorded performance and nutritional status, as well as the 
presence of comorbidities, particularly cardiopulmonary chronic disease that is common in 
this population [8, 16].  
Recent evaluations have highlighted disappointing long-term results in terms of OS 
regarding different non-surgical organ-sparing protocols. Considering this end-point, in 
fact, deaths unrelated with LC were interestingly higher after CCRT (30.8%) if compared 
with those following IC (20.8%) or RT (16.9%) [17]. It was strongly suspected a toxic role 
in CCRT leading to increasing fatal occurrences. Anyhow further investigations would be 
necessary to definitively determine the causative differences [17]. 
Beyond oncologic end-points, some Authors noticed many other disadvantages. First of 
all, suffering from numerous comorbidities (e.g. low renal and hepatic functions, poor 
performance status and insufficient compliance) old and very old patients could not 
tolerate chemo-radiotherapy approaches. Furthermore, in case of locally advanced LC 
with deranged laryngeal function prior the treatment or large cartilage destruction, any 
attempt to preserve the larynx by means of RT or CCRT protocols is hazardous. In fact, it 
should be always provided enough residual laryngeal cartilage to afford a high likelihood of 
mechanical stability and / or post-therapy regeneration [13, 18-20]. This finding, according 
to some Authors, associates laryngeal preservation in T4 LC with a high incidence of acute 
toxicity and disruption in laryngeal function, in term of significant pharyngeal and 
esophageal edema, fibrosis and stenosis, xerostomia with diminished perception of 
swallowing functions and aspiration, acute mucositis and dysphagia. Table 3 reported 
acute and late toxicities observed in the same studies previously mentioned encouraging 
organ-sparing protocols. 
On the other hand, patients undergone TL develop some irrefutable sequelaes: loss of 
normal voice, swallowing problems, loss of nasal function, altered smell and taste, poor 
cough, lung function changes, tracheostomal complications, and lifelong functional and 
psychological consequences [21]. However, the sole preservation of the larynx does not 
 
 
7 
guarantee its function. A patient with an intact but functionless larynx may be unable to 
swallow, with consequently respiratory complications. The quality of life of an individual 
with complications after a chemo-radiation protocols may be worse than that of a patient 
who has undergone a successful TL, who is able to eat and to breathe normally and who 
can talk with the aid of tracheo-esophageal puncture or by esophageal voice [22].  
Voice rehabilitation in laryngectomy patients has been achieved in the past with surgical 
shunts, esophageal speech, electrolarynx devices, and others. Each of these methods has 
its advantages and disadvantages. However, since the introduction of voice prosthesis, 
tracheo-esophageal speech with voice prosthesis (T-E speech) is the accepted standard 
of care in voice rehabilitation after laryngectomy. In fact, it provides a lung-powered 
speech and, hence, a physiologically better voice quality [23].  
Based on these considerations and focusing the attention only on T4a LC, the up-front 
surgery with post-operative radiotherapy is the best treatment choice.  
As indicated by the most adopted worldwide guidelines, TL remains the standard of care, 
even with the cost of laryngeal organ loss; chemo-radiation protocols are treatment options 
for the minority of highly selected patients with smaller-volume cancers, intact airway 
protection and swallowing function, good performance status and inadequate compliance 
to a surgical option as well as for patients who firmly reject the radical surgery. 
 
Emerging role for partial laryngeal surgery in selected T4 laryngeal cancer 
 
The same overarching goals of non-surgical organ preservation, meaning to spare the 
function without compromising the oncological outcome, have always spurred surgeons to 
look for technical solutions, which brought to a renaissance of conservative laryngeal 
surgery. Born from the brilliant intuitions of true Pioneers [24-28], this type of surgery has 
been acknowledged in recent years of multiple published studies (sometimes from large 
multi-centric series), which gave a significant boost in the understanding of its benefits and 
drawbacks. In fact, these procedures had proven to be viable options for the management 
of early-stage LC, but showed reasonable limits especially with advanced-stage cases. 
The main clinical difficulty in facing advanced-stage tumors lies in preoperative diagnosis, 
since the efficiency of imaging techniques (CT-scan and MRI) in detecting infiltration of the 
thyroid cartilage does not achieve a total diagnostic accuracy [29]. Radical control of 
disease by a transoral approach (TLM and TORS) cannot be achieved when the lesion 
involves the laryngeal framework and/or when it tends to grow outside the laryngeal box 
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[30, 31]. In fact, anterior encroachment of the thyroid cartilage, crico-thyroid or thyro-hyoid 
membranes makes the tumor at risk of persistence after TLM even when removals of a 
cartilage fragment or its extensive vaporization is carried out. Therefore, Peretti and 
colleagues stated that involvement of the posterior paraglottic space with encroachment of 
the crico-arytenoid joint and infiltration of the laryngeal framework negatively influence 
both oncological and functional results, thus limiting the role of TLM to anecdotal cases 
[32]. Supracricoid laryngectomy and the more recent supratracheal laryngectomy emerged 
as options for these advanced cancers inasmuch as they still achieve acceptable levels of 
locoregional control rate and contextually allow the maintenance of a functional larynx.  
The factors that must be taken into account before offering the OPHL option to a patient 
suffering from locally advanced LC are diagnosis of a tumor belonging to favorable T-
related disease subsets, performance and functional status of the patient, presence of 
comorbidities, compliance to a sometimes demanding rehabilitation protocol, plausible 
need of adjuvant RT.   
A multidisciplinary team evaluation, in a high-experienced Center, as well as an accurate 
diagnostic work-up resulting from the strong collaboration with Radiologists, are the key to 
achieve good functional outcomes and minimize the risk of recurrence development and 
the consequent need of salvage laryngectomy, albeit in a limited number of LC in stage 
T4a [33].  
Despite many T4a cases had been successfully treated with OPHL and had been reported 
on single institution series (Table 4), the current evidence-based guidelines do not suggest 
their employment for the management advanced LC cases, even when the patient refuses 
the radical surgery. 
Recently, Succo et al. carefully analyzed results achieved in different subcategories of cT3 
and cT4a LC treated with OPHL, which were conducted using the principle of a modular 
approach. The Authors stated that glottic or supraglottic T4a tumors with full-thickness 
involvement of the thyroid lamina and/or minimal extralaryngeal extension, but not 
interesting the posterior paraglottic space and not affecting the mobility of the arytenoid, 
are those amenable to be treated by OPHL, showing the greater probability of success 
[34]. The principle underlying the modular approach means that the resection is always 
prepared in standard mode and the larynx is opened from the side less affected by 
disease. At this point, under visual control, the sub-sites involved are removed and the 
radicality checked by the frozen sections. 
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In the clinical practice, such cases are the same that current guidelines consider as 
amenable to non-surgical organ sparing protocol, if the patient refuses the TL. The choice 
of OPHL with a modular approach instead of CCRT in favorable disease subsets could be 
considered to be viable not only in prognostic terms, but also as functional results, e.g. a 
reduction in the number of total laryngectomies. 
Furthermore, Authors stated also that the radicality is the same achievable with more 
demolitive interventions, but the selection of patients must be made very carefully. Indeed, 
at the end of the work-up, the surgeon must be able to ensure safe margins with sufficient 
certainty, thus avoiding an up-front TL. 
 
Salvage surgery in locally advanced laryngeal cancer 
 
With the increasing use of chemoradiation as primary treatments also for advanced LC, 
the loco-regional complications related to failure of these treatments have increased in 
term of persistent or recurrent disease, laryngeal dysfunction or radionecrosis and severe 
neck fibrosis [35]. 
Despite endoscopy and the availability of modern imaging studies, diagnosis of recurrent 
or persistent tumor may be difficult. The main hurdles reside in: different growth pattern of 
radio-recurrent LC with respect to that of primary carcinoma, multiple tumor foci localized 
below an intact mucosa that are masked by edema and fibrosis, confused patient reported 
symptoms, and impaired laryngeal mobility [36].  
In this scenario, salvage surgery represented the only therapeutic weapon available (Table 
5). Regarding the advanced LC, salvage TL remains the gold standard, whereas the 
employment of organ-sparing protocols such as the OPHL could be considered anecdotal. 
In case of salvage after CCRT failure, there is no reason to debate about the indication of 
TL.  
Salvage TL is certainly more prone to complications as compared to the up-front one. 
Evidences from the literature reported that complications after salvage TL are higher in 
patients undergoing CCRT than in patients treated by RT alone. In fact, chemotherapy 
deteriorates general health, nutritional and performance status of the patient. Furthermore, 
exacerbating the obliterative endoarteritis and fibrosis induced by radiation in local tissues, 
it participates to the creation of micro-vascular damage with tissue hypoxia and impaired 
wound healing [37]. 
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The most common major complication of TL, and in particular in case of salvage one, is 
pharyngocutaneous fistula (PCF). 
To avoid the PCF complications, several studies analyzed the role of “onlay” vascularized 
flap reconstruction with the rationale to incorporate no-irradiated well vascularized tissue to 
aid hypoxic tissues and consequently wound healing, reinforce the pharyngeal repair site 
or augment the circumference of the neopharynx. The incidence of PCF is higher after 
primary closure than after closure with the interposition of a well vascularized flap (Table 
6).  
The salivary bypass tube is another useful device with positive results in reducing the risk 
of PCF. In fact, it can be used to stent the reconstruction, calibrate the new digestive tract, 
and decrease salivary exposure of the anastomotic suture line. Consequently, the 
pharyngoesophageal reconstruction rapidly heals and the rate of fistula and stricture 
decreases [38, 39]. 
However, the morbidity associated with a PCF is undoubtedly greater, thus supporting the 
aphorism that “prevention is better than any subsequent management and treatment of 
PCF” [31]. 
 
Difficulties in assessing long term quality of life and laryngeal function 
 
Following the extensive application of non-surgical preservation protocols in the treatment 
of locally advanced LC, the need to identify functional endpoints able to reflect more 
closely the aspects of the real quality of life after treatment arose. In fact, despite side 
effects correlated with TL are evident (decrease in all communication related parameters), 
those induced by chemo-radiotherapy on life quality and functional outcomes (e.g. 
swallowing) may not always be correlated with an anatomically preserved larynx [40]. 
Findings concerning functional outcomes from retrospective series are limited by the lack 
of consistent / uniform data collection, instrumental swallowing evaluation, and patient-
reported outcomes with validated metrics [13]. 
In 2009, the Larynx Preservation Consensus Panel [10] identified four composite 
functional/mortality endpoints in designing larynx preservation trials: 1) LED: 
laryngoesophageal dysfunction free survival (any death, local disease recurrence, salvage 
total laryngectomy, tracheotomy and/or feeding tube placement/persistence after 2 years 
as an event, censoring all others); 2) LxFS: laryngectomy-free survival (the date of salvage 
or completion total laryngectomy or the date of death, censoring all others); 3) FFL: 
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actuarial freedom from laryngectomy (the date of salvage or completion total 
laryngectomy, censoring all others); and 4) FFLED: actuarial freedom from 
laryngoesophageal dysfunction (local disease recurrence, salvage total laryngectomy, 
tracheotomy and/or feeding tube placement/persistence after 2 years as an event, 
censoring all others including deaths). 
The limited number of patients available for long-term effect analysis, due to the low OS 
after CCRT, and the lack of correlation between patients’ perceptions and objective 
studies resulted in a reduced statistical power, and highlighted the importance of 
documenting swallow function before, during, and after chemo-radiation treatment [31]. 
Therefore, it is currently not possible to draw an accurate picture of the real benefits of the 
laryngeal preservation in terms of quality of life. In the RTOG study, severe late toxicity 
was reported in 43% of patients at the long-term analysis [17]. Anyhow, further 
investigations with properly designed studies specifically addressing laryngeal function are 
needed. 
Analyzing the telephone intelligibility of LC patients undergoing different therapeutic 
approaches, Crosetti et al. [41] recently found that more aggressive surgery as well as 
chemo-radiotherapy correlated with significantly poorer outcomes. Otherwise, TLM or RT 
alone ensured the best telephonic voice intelligibility. Intermediate-advanced T stages at 
diagnosis also showed significantly poorer intelligibility outcomes, suggesting that T stage 
represents an independent negative prognostic factor for voice intelligibility after treatment. 
 
Conclusions 
 
After several years in which TL seemed to fade, it returned to great actuality.  
Long-term survival is achievable for patients with T4a LC and the most negative prognostic 
factor is represented by N status. Currently new strong evidences are confirming the role 
of TL as up-front treatment for advanced LC or salvage treatment in case of organ sparing 
protocols’ failure.  
CCRT option presents worse results in terms of oncological and functional rates, 
principally in T4a cancers and in patients with poor general conditions. Therefore, non-
surgical laryngeal preservation should be addressed to carefully selected patients who 
refused TL, characterized by more limited T4 disease, minimal involvement through the 
cartilage without derangements of laryngeal function prior the treatment. 
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OPHL, to the light of good and encouraging oncological results, could represents an 
alternative to TL only for selected patients affected by LC in specific T4 subcategories (in 
particular for those with anterior extension).  
Nowadays, however, TL-PORT remains the gold standard of treatment in locally advanced 
LC, with stable and acceptable results in terms of oncological, functional and life quality 
outcomes. 
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Table 1 Studies analyzing organ sparing protocols 
 
Author - year 
publication 
N° of patients 
Cancer site and 
staging 
Treatment modalities LP OS 
VALCSG, 1991 [8] 332 pz Larynx, III-IV 
PF -> RT vs 
S -> RT 
64% 68%/2 ys 
EORTC 24891 [42] 202 pz, 
Hypo pharynx, 
II-IV 
PF -> RT vs 
S -> RT 
22%/5 ys 
- PF -> RT 38% / 5 ys 
- S -> RT 33%/5 ys 
GETTEC [43] 68 pz Larynx, II-IV 
PF -> RT vs 
S -> RT 
42% 
 
- PF -> RT 69% / 2 ys 
- S -> RT 84%/2 ys 
RTOG 91,11 [17] 547 pz Larynx, III-IV 
PF -> RT vs 
CRT vs 
RT 
- PF -> RT 71%/5 ys 
- CRT 84%/5 ys 
- RT 66%/5ys 
- PF -> RT 59%/5 ys 
- CRT 55%/5 ys 
- RT 54%/5ys 
GORTEC 2000-01 
[44] 
213 pz 
Larynx, 
Hypo pharynx, III-IV 
PF -> RT vs 
TPF -> RT 
- PF -> RT 57% /3 ys 
- TPF -> RT 70%/3 ys 
- PF -> RT 60% /3 ys 
- TPF -> RT 60%/3 ys 
EORTC 24954-
22950 [45] 
450 pz 
Larynx, 
Hypo pharynx, III-IV 
PF -> RT vs 
aPF -> RT (6w) 
- PF -> RT 48%/5ys 
- aPF -> RT (6w) 52%/5ys 
- PF -> RT 53%/5ys 
- aPF -> RT (6w) 60%/5ys 
POSNER [46] 166 pz 
Larynx, 
Hypo pharynx, III-IV 
PF -> CRT vs 
TPF -> CRT 
- PF -> CRT 32% LFS / 3ys 
- TPF -> CRT 52% LFS/3 ys 
- PF -> CRT 40% / 3 ys 
- TPF -> CRT 57% /3 ys 
TREMPLIN [47] 153 pz 
Larynx, 
Hypo pharynx, III-IV 
TPF -> CRT vs 
TPF -> Cet+RT 
- TPF -> CRT 93% 3 months 
- TPF -> Cet+RT 93% 3 months 
- TPF -> CRT 85% 1,5 ys 
- TPF -> Cet+RT 86% 1,5 ys 
PRADES [48] 71 pz Pyriform sinus, III-IV 
PF -> S or RT vs 
P-RT 
- PF -> S 68%%2 ys 
- RT vs P-RT 92% / 2 ys 
- PF -> S DFS36%%2 ys 
- RT vs P-RT DFS41% / 2 ys 
YS= years, S= surgery, LP= larynx preservation, OS= overall survival, DFS= disease free survival, LFS= laryngectomy free-survival, 
CRT= chemo radiation, PF=platinum-fluorouracil, T= Taxotere, Cet= Cetuximab 
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Table 2 Studies analyzing total laryngectomy and organ-sparing protocols for T3-T4a laryngeal cancer 
 
Author year 
Type of 
study 
N 
Cancer 
staging 
Treatment OS DSS e DFS LRC LP , LEDFS Conclusions 
Bussu, 2013 
[49] 
Retrospective 
cohort study 
166 T3-T4a 
TL, OPHL, 
CRT 
T4a 3 ys - TL 78% 
- OPHL 68% 
- CRT 54% 
DSS  
87%/2ys 
 
T3+T4a: 
CRT 45% 
OPHL 77% 
In whole series no stat sign in 
the 3 arms for OS and DSS.  
Francis, 2014  
[20] 
Retrospective 
cohort study 
and review 
108 
 
24 
studies 
T4a TL, RT, CRT 
81%/2 ys 
60%/5 ys  
Review:  
/ 2aa:  
- LT 30-100% 
- RT 12-21% 
- CRT 30-65% 
   
Primary TL provides a high 
survival rate for T4a. 
High rate of laryngeal 
dysfunction after CRT. 
Dziegielewski, 
2012 [50] 
Longitudinal 
cohort study 
258 T3,T4 
TL-
PORT/CT, 
RT, CRT 
2ys -5ys T3: 
-  TL- PORT /CT 2 ys 
89%   
5 ys 70% 
- RT 2 ys 48%  
5 ys 18% 
- CRT 2 ys 66%  
5 ys 52% 
OS / 2 e /5 aa T4a: 
- TL-PORT/CT 2 ys 
60%   
5 ys 49% 
- RT 2 ys 12%  
5 ys 5% 
- CRT 2 ys 32%  
5 ys 16% 
 
DFS / 2ys T3: 
- TL-PORT/CT  
94% LRC - 0% LP 
- RT  
66% LRC - 28% LP 
- CRT  
LRC 53% LCR -48% 
LP 
 
DFS/ 2ys T4a: 
- TL-PORT/CT 
67% LRC - 0% LP 
- RT  
30% LRC -  3% LP 
- CRT  
54% LRC - 29% LP 
  
TL-R/CT provides superior 
survival for T3 and T4a LC 
versus RT or CRT.  
Grover, 2014 
[51] 
Retrospective 
cohort study  
969 T4a 
TL-PORT 
and LP-CRT 
Median OS: 
- TL-PORT 61 
months 
- LP-CRT 39 months 
   
Patients with T4a LC receiving 
LP-CRT had more advanced 
nodal disease and worse OS. 
Previous studies of (non-T4a) 
locally advanced LC showing 
no difference in OS between 
LP-CRT and TL may not apply 
to T4a disease. 
Timmermans, 
2014 [19] 
Retrospective 
cohort study 
182 
T3 and 
T4 
TL-PORT 
(91% T4), 
RT, CRT  
OS / 5 ys T3: 
- TL-PORT 49% 
- RT 47% 
- CRT 45% 
OS / 5 ys T4a: 
- TL-PORT 48% 
- RT 34% 
- CRT 42% 
 
T3+T4a: 
- TL-PORT 
87% 
- RT 65% 
- CRT 76% 
 
No differences in survival.  
T3 : > CRT 
T4: > TL-PORT 
Timmermans, 
2015 [52] 
Population 
based study 
2072 T3 
and 
1722 T4 
T3-T4 
TL-
PORT/CT, 
RT and CRT 
OS / 5 ys T3: 
- TL-PORT/CT 49% 
- RT 47% 
- CRT 45% 
OS / 5 ys T4a: 
- TL-PORT/CT 48% 
- RT 34% 
- CRT 42% 
  
LFI T3: 
- RT 81% 
- CRT 77% 
 
 
LFI T4a: 
- RT 81% 
- CRT 87% 
For T4 disease, TL-PORT 
showed the best survival 
Timme, 
2015 [53] 
Retrospective 
cohort study 
71 T3 - T4 
TL or PL, 
CRT  
/5 ys T3: 
- TL or PL 41% 
- CRT 40% 
/5 ys T4a: 
- TL or PL 54% 
- CRT 53% 
  
LP total CRT 
79% 
 
LEDFS 40% 
T3, 33% T4a 
CRT : high rate of laryngeal 
and oesophageal dysfunction. 
Rosenthal, 
2015 [14]  
Retrospective 
cohort study 
221 pz T4a 
TL-PORT 
and LP-CRT  
median OS  
- TL-PORT 47-48 
months 
- LP 38 months 
DSS/5 ys  
- TL-PORT 60% 
- LP 48,5% 
ys : 
- TL-PORT 
84%  
- RT 63% 
 
TL-PORT can produce 
substantial long-term cancer 
control and survival rates for 
patients with T4 larynx cancer. 
Luo, 2015 [54] 
Meta-analysis 
and review 
2013 pz T3-T4a 
TL-PORT, 
IC-RT, CRT, 
RT alone 
OS: 
- TL-PORT 66% 
- IC-RT 60,8% 
- CRT 61% 
- RT alone 71,6% 
DFS: 
- TL-PORT 56,6% 
- IC-RT 41% 
- CRT 44,9% 
- RT alone 57,8% 
DSS 55-70%/5ys 
  
RT alone better OS, DFS, and 
LFS in patients with locally 
advanced LC. TL >DFS, but OS 
were similar across the different 
larynx-preserving treatments 
and TL. 
Rodrigo, 
2015 [55]  
80 pz T3-T4a TL OS/5 ys 55% DSS / 5 ys 72%   
TL is an effective treatment for 
the management of patients 
with locally advanced LC 
Gorphe, 
2016 [56] 
Retrospective 
cohort study 
100 pz T4a TL-PORT 
OS/ 2 ys 65% 
OS/ 5 ys 52,4% 
OS/ 10 ys 33,3% 
DFS/ 2 ys 55% 
DFS/ 5 ys 42,6% 
DFS/ 10 ys 31,8% 
LCR/ 2 ys 
77% 
LCR/ 5 ys 
74% 
LCR/10ys65,9 
 
Surgery for T4a larynx cancer 
remains a standard of care 
Fu, 2016 [1] Meta-analysis   
T3 and 
T4a 
TL-PORT 
and LP-CRT 
OS/2 ys  
- TL-PORT 78,8%  
- LP-CRT 52,9%  
OS/5 ys  
stat sign only T4a 
 
 
LC/2 ys 
- TL-PORT 
76% 
- LP-CRT 
54,6% 
LC/5 ys  
Not stat sign 
 
TL-PORT significant advantage 
in OS and LCR T4a laryngeal 
cancer 
Sanabria 
2016 [57] 
Review  
T3 and 
T4a 
TL, CRT 26%    
Evidence supports total 
laryngectomy for patients with 
T4 cancers. T3 possible CRT 
Al-Gilani, 
2016 [58] 
Retrospective 
cohort study 
487 pz T3 
Surgery vs 
LP-CRT 
OS 5/ ys 
- surgery 41% 
- CRT 36%  
   
OS > in pz with T3 glottic SCC 
who underwent surgery 
compared with a nonsurgical 
treatment. Furthermore, 
adjuvant and nonsurgical 
treatment result in a 
dysfunctional larynx 
Succo, 2016  
[34] 
Retrospective 
cohort study 
555 
pT3-
pT4a 
OPHL 
84,6% / 5 ys 
pT3 87,8% 
pT4a 71,2% 
DFS 84,2% 
pT3 87,9% 
pT4a 68,1% 
LRC 86,3% 
pT3 89,7% 
pT4a 71,7% 
LFP 91,2% 
pT4a 78,0% 
 
LFS 93,3% 
Evidence supports open partial 
laryngectomy for selected 
patients with T4a cancers with 
anterior extension   
YS= years, PZ= patients, OS= overall survival, DFS= disease free-survival, DSS= disease specific survival, LP= larynx 
preservation, LFI = laryngectomy free interval, LEDFS = laryngoesophageal dysfunction-free survival 
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Table 3: Acute and delayed toxicities 
Author - year 
publication 
Treatment modalities Acute toxicity Late toxicity 
VALCSG, 199 [19] 
PF -> RT   
S -> RT 
TD 3; mucositis 38% 
TD 5 ; mucositis 24% 
 
EORTC 24891 [42]  
PF -> RT vs  
S -> RT 
7 toxic effects, 1 TD 
1 vascular disease, 1 depressive illness  
GETTEC [43]  
PF -> RT vs  
S -> RT 
Digestive 3%, hematological 1% 
Digestive 0%, hematological 0% 
 
  
RTOG 91,11 [17] 
PF -> RT vs  
 
 
CRT vs  
 
 
RT 
Hematological 52% mucositis 34%, laryngeal 13% 
 
 
Hematological 47% mucositis 43%, laryngeal 18%  
 
 
Hematological 3%  mucositis 34%, laryngeal 16% 
Skin toxicity 5-0%, mucosal 5-0%, larynx toxicity 1-6%, 
dysphagia 15-3%, subcutaneous 11-1% 
 
Skin toxicity 1-0%, mucosal 3-0%, larynx toxicity 17-6%, 
dysphagia 22-3%, subcutaneous 9-1% 
 
Skin toxicity 2-1%, mucosal 3-1%, larynx toxicity 21-3%, 
dysphagia 22-2%, subcutaneous 9-2% 
GORTEC 2000-01 
[44] 
PF -> RT vs  
 
 
 
TPF -> RT 
2TD, neutropenia 17,6%, infections 5,8%, 
stomatitis 7,8%, thrombocytopenia 7,8%, 
creatinine elevation 2% 
 
5TD, neutropenia 31,5%, infections10,9%, 
stomatitis 4,6%, thrombocytopenia 1,8%, 
creatinine elevation 0% 
G4 larynx toxicity 13,6%, mucosal 0%, xerostomia 2,2%, 
subcutaneous 6,6% 
 
 
G4 larynx toxicity 6,2%, mucosal 1%, xerostomia 6,1%, 
subcutaneous 4% 
EORTC 24954-
22950 [45] 
PF -> RT vs  
aPF -> RT (6w) 
Mucositis 32%, skin reaction 6%, dysphagia 33% 
Mucositis 21%, skin reaction 0%, dysphagia 20% 
Mucosal 25%, neuropathy 14%, subcutaneous 31% 
Mucosal 28%, neuropathy 11%, subcutaneous 28% 
TREMPLIN [47] 
TPF -> CRT vs 
 
 
TPF -> Cet+RT 
Mucositis 43-3% 
 
 
Mucositis 52-2% 
 
Mucosal 3,5%, xerostomia 10,3%, subcutaneous fibrosis 7%, 
neuropathy 3,4%, laryngoesophageal 8,6% 
 
Mucosal 1,8%, xerostomia 8,9%, subcutaneous fibrosis 2%, 
neuropathy 0%, laryngoesophageal 9,0% 
TD = toxic deaths 
 
  
 
 
16 
Table 4 Studies analyzing OPHL potentiality also for advanced laryngeal cancer 
 
Author year N 
Cancer 
staging 
Treatment OS DSS e DFS LC/LRC LFP LFS % Complications % Recurrence 
Bocca, 1983 
[59] 
467 T2-T4a OPHL type I  OS / 5 ys 75,0%       
Chevalier, 
1997 [60] 
61 
T1-T4a 
T1 2 
T2 41 
T3 14 
T4 4 
OPHL type II 
OS / 3 ys 83% 
OS / 5 ys 79% 
     3,0% 
Laccourreye, 
1998 [61] 
60 T3-T4a 
Neo-adjuvant CT 
- OPHL type II 
87,9% / 3 ys 
72,7% / 5 ys 
 98,3% 91,7%  8,3% local failure  
De Vincentiis, 
1998 [62] 
149  
OPHL type II 
(CHP 98 pz 
CHEP 51 pz) 
2 groups: 
OS 1° 88,1%  
OS 2° 95,0% 
  98%   6,0% 
Bron, 2000 [63] 69 
T1-T4a 
pT1 10 
pT2 30 
pT3 9 
pT4 5 
local 
relapse15 
OPHL type II 
 
13% adjuvant RT 
OS / 5ys 66,5% 
- glottic : 69,1% 
- supraglottic : 
45,6% 
DSS /5 ys 
80,1% 
- glottic : 83,2% 
- supraglottic : 
51,4% 
LC/5 ys 84,0% 
LCR no RT Pz 
94,5% 
 87,0% 49,1% 6,1% 
Gallo, 2005 
[64] 
253 
T1-T4a 
T1 27 
T2 147 
T3 64 
T4 15 
OPHL type II 
180 CHP 
73 CHEP 
85,8% / 3 ys 
79,1% / 5 ys 
57,6% / 10 ys 
57,6% / 16 ys 
 LRC 91,3% 92,1%   8,7% 
Lima, 2005 [65] 43 
T3-T4a 
glottic 
OPHL type II 
(CHEP) 
 
DSS / 5 ys 
78,0% 
DFS / 5 ys 
83,0% 
LRC / 5 ys 
85,0% 
  25,5%  
Laudadio, 2006 
[66] 
206 
T1b-T4a 
T1b 66 
T2 89 
T3 46 
T4 5 
OPHL Type II 
9,2% CHP 
90,8% CHEP 
pT3 88,7% 
pT4 78,9% 
DFS / 3 ys 
85,4% 
DFS / 5 ys 
85,0% 
pT3 77,6% 
pT4a 53,8% 
    15,0% 
Rizzotto, 2015 
[67] 
115 
T2-T4a 
pT2 14 
pT3 50 
pT4a 51 
OPHL Type III 
78,9%/5ys 
pT4a 80,4% 
DFS 68,5% /5 
ys 
pT4a 60,8% 
69,6% / 5 ys 
pT4a 62,7% 
 
LFP 78,3% 
pT4a 59,3% 
6,1% acute 
24,4% late 
 
Succo, 2016 
[34] 
555 pT3-pT4a OPHL 84,6% / 5 ys pT4a 68,1% pT4a 71,7% pT4a 78,0% 93,3%   
LFP= laryngeal function preservation, LFS = laryngectomy free survival, LC = local control 
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Table 5 Complications, survival outcomes and prognostic risk factors in patients with salvage surgery after organ-sparing 
protocols for SCC of larynx 
 
Author - year 
publication 
N° of 
patients 
Previous 
treatment 
Salvage 
surgery 
Complica
tions 
Fistula LR OS DSS Risk factors  
Paleri, 2011 [68] 350 CRT SPL   87%/2ys 83%/3ys 91%/2ys  
Putten, 2011 [69] 120 CRT STL   70%/5ys 50%/5ys 58%/5ys 
Risk factors: level of albumin and 
hemoglobin, N+ 
Klozar, 2012 [70] 208 CRT STL  34%     
Erdag, 2013 [71] 36  STL  50%     
Sewnaik, 2012 
[72] 
24 CRT STL 92%      
Patel, 2013 [73] 359 CRT STL 
 
27%    
 
De Vincentiis, 
2013 [74] 
68 (C)RT - TLM 
SPL (23 pz) 
STL (45 pz)  
    
OS and DFS < STL than SPL (prognostic 
factor involvement of resection margins) 
Santoro, 2013 
[75] 
75 RT 
SPL (16%) 
STL (84%)  
32,7%    
OS and DFS < STL than SPL (prognostic 
factor rT) 
Li, 2013 [76] 100 CRT STL 
 
 70%/5 ys  
55-70%/ 
5ys  
Basheeth, 2013 
[37] 
45 CRT STL 44%     
 
Sayles, 2014 [77] 33 studies 
CRT 
RT alone 
STL 
 
34% 
22,8% 
   
 
Sayles, 2014 [77] 33 studies CRT 
PTL 
STL  
14,3% 
27,6% 
   
 
Timmermans 
2014 [78] 
98 CRT STL 
 
26%    
 
Powell, 2014 [79] 45 CRT STL 
 
22%    
 
Süslü, 2015 [80] 151 CRT STL 
 
13%    
 
Busoni, 2015 [81] 86 
PTL 
STL post –RT 
STL post-CRT 
 
 
19% 
 
28,6% 
 
30,3% 
   
 
Putten, 2015 [82] 22 CRT STL 73% 23% 58%/5ys 27%/5ys 36%/5 ys 
 
Wulff, 2016 [83] 142 CRT STL 60% 41,6%  37,7%/5ys 54,9%/5ys N+ and positive margins 
STL = salvage total laryngectomy, SPL salvage partial laryngectomy 
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Table 6 Comparison of PCF in patients with salvage laryngectomy with and without flap reinforcement 
 
Author - 
year 
publication 
N° of 
patients 
Treatment Fistula with flap 
Fistula without 
flap 
Results and conclusions 
Patel, 2009 
[84] 
359 
PMF 
FVT 
15% 
25% 
34% 
With PMF reinforcement, PCFrate after 
salvage laryngectomy dropped to 0% in 
this study 
Busoni, 2013 
[81] 
20 
Conservative 
FVT 
  
Fistula after PTL  conservative 
treatment 
Fistula after STL  flaps 
Santoro, 2013 
[75] 
29 
Conservative 
FVT 
80,5% 
8,3% PFM 
21% local flaps 
34% Flaps reduce the risk of fistula 
Powell, 2014 
[79] 
45 FVT/PMF 0% 26% 
lower rate of PCF with tissue transfer 
compared with primary closure of the 
neopharynx. 
Sayles, 2014 
[77] 
33 studies Onlay flap 10% 28% 
Prophylactic flaps used in an "onlay" 
technique reduce fistula incidence in 
STL 
Paleri, 2014 
[35] 
591    Flaps reduce the risk of fistula 
Anschutz, 
2016 [85] 
48 PMMF 0% 42,1% 
PMMIF is useful to prevent PCF in STL 
following CRT.  
PMF = pectoralis myofascial flap, FVT = free vascularized tissue  
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